Navigation Links
Riveting Biotechnology Novel, WIRED, Becomes the #1 Technothriller on Amazon
Date:1/21/2013

New York, New York (PRWEB) January 21, 2013

The runaway biotech bestseller, WIRED, was not only a New York Times and USA Today bestseller, but the bestselling Kindle novel of 2011 in two major categories—science fiction and technothrillers—an unprecedented achievement.

Now, as the WIRED sequel, AMPED, climbs the charts to glowing reviews, the eBook version of WIRED has regained the top spot on Amazon's technothriller list, and is being offered on Amazon for only $5.95. The author of these books, Douglas E. Richards, has been frequently compared to the late Michael Crichton for his ability to weave action, suspense, and well-researched science into riveting page-turners.

Richards has a master's degree in genetic engineering and was a biotechnology executive for many years. "When I wrote WIRED," he explains, "I asked myself the question: what if it were possible to boost human IQ to immeasurable levels for short periods of time? What capabilities might this confer? What changes to attitude and personality? Would this bring out our better angels or unleash our darker sides, causing us to grow ever more drunk with power?"

Both WIRED and AMPED answer these questions in a way that bestselling author Boyd Morrison calls, "action-packed, breathtaking, and mind-blowing."

According to SFRevu founder, Ernest Lilley, "WIRED has a twisty plot, big ideas, and nonstop action and intrigue. It'll have you guessing until the very end."

To learn more about Richards and his work, visit his website at http://www.douglaserichards.com or Friend him on Facebook at Douglas E. Richards Author.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10341024.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Riveting Biotechnology Novel, WIRED, Becomes the #1 Technothriller on Amazon
2. Riveting Biotechnology Novel, WIRED, Becomes the #1 Technothriller on Amazon
3. Puma Biotechnology Announces Completion of Private Placement
4. Animal Biotechnology - Technologies, Markets and Companies
5. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
6. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
7. JumpStart Invests $250,000 in Milo Biotechnology
8. Global Biotechnology Industry
9. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
10. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
11. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
(Date:6/22/2016)... 2016 Research and Markets has announced the ... to their offering. The ... $29.3 billion in 2013. The market is expected to grow at ... to 2020, increasing from $50.6 billion in 2015 to $96.6 billion ... the forecast period (2015 to 2020) are discussed. As well, new ...
(Date:6/22/2016)... ... June 21, 2016 , ... New light-based technologies that facilitate a “look inside” ... to enable both compact, wearable devices for point-of-care diagnostics as well as powerful new ... Recent work and visionary future directions are detailed in a new open-access article by ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):